Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Invitation to presentation of Q1 report

Wed, Apr 27, 2022 15:00 CET

STOCKHOLM — April 27, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that it will present the interim report for the first quarter 2022 on May 4, at 11:00 (CET), and that the Annual General Meeting in Oncopeptides AB (publ) will be held on Tuesday June 28, 2022, (changed from May 19, 2022).Investors, financial analysts, and media are invited to participate in a webcast including a QnA session on May 4. The event will be hosted by CEO, Jakob Lindberg and

Invitation to presentation of the Q3 2021 results

Fri, Nov 19, 2021 15:00 CET

STOCKHOLM — November 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish its report for the third quarter 2021 on November 24. Investors, financial analysts, and media are invited to participate in a webcast with a QnA session on the same day at 10:00 CET. The event will be hosted by CEO, Jakob Lindberg and members of the Oncopeptides’ Leadership team. The presentation will be held in English.The webcast will be streamed via this link

Invitation to presentation of the Q2 2021 results

Thu, Aug 12, 2021 13:00 CET

STOCKHOLM — August 12, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish its report for the second quarter 2021 on August 19. Investors, financial analysts, and media are invited to participate in a webcast with a QnA session on the same day at 12:00 CEST. The event will be hosted by CEO, Marty J Duvall and members of the Oncopeptides’ Leadership team. The presentation will be held in English.The webcast will be streamed via this link

Interim Report April-June 2018

Fri, Jul 13, 2018 08:00 CET

“General knowledge and understanding of Oncopeptides and our clinical strategy has greatly increased during the spring”Summary of Q2 Financial overview April 1 – June 30 2018 · Net sales amounted to 0.0 (0.0) MSEK · Loss for the period was 143.1 (loss: 67.3) MSEK · Loss per share, before and after dilution, was 3.27 (loss: 1.69) SEK · On June 30 cash and cash equivalents amounted to 568.2 (535.1) MSEK Significant events during the period April 1 to June 30 2018 · First patient started treatment with Ygalo® in the Phase I/II study ANCHOR · A Clinical

Oncopeptides AB Interim report January – March 2018

Thu, May 17, 2018 08:00 CET

Stockholm — May 17, 2018 — Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2018 report."Important milestones have been achieved in the first quarter” Summary of Q1 Financial overview January 1 – March 31 2018 · Net sales amounted to 0.0 (0.0) MSEK · Loss for the period was 62.0 (loss: 62.1) MSEK · Loss per share, before and after dilution, was 1.56 (loss: 1.89) SEK · On March 31st cash and cash equivalents amounted to 664.9 (611.6) MSEK Significant events during the period January 1 – March 31 2018 · In March, the company strengthened

Oncopeptides AB Interim Report July - September 2017

Wed, Nov 15, 2017 08:00 CET

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the third quarter 2017 report. “The data from our study, O-12-M1, provides us with an increased degree of comfort regarding a positive clinical outcome in our pivotal study OCEAN” SUMMARY OF Q3 July 1st – September 30th 2017 Significant events after the period · Net sales amounted to 0.0 (0.0) July 1st to September 30th 2017MSEK · On November 1st, we announced that · Loss for the period was 51.6 we will present results from two(loss: 24.7) MSEK

Oncopeptides AB Interim Report January - March 2017

Thu, May 18, 2017 08:00 CET

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2017 report. ”Our IPO received strong interest both from Sweden and internationally, including several well-renowned institutional long term investors. We are now fully financed to drive our broad clinical development program in late-stage multiple myeloma patients, including a phase II trial to be initiated and the ongoing phase II trials and the pivotal phase III trial OCEAN.”SUMMARY OF Q 1 January 1st – March 31st 2017 · Net sales amounted to 0.0 (0.0) MSEK · Loss for the period

There are no items matching the current filter

There are no more items matching the current filter

Share